Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Neoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and to judge the impact of response to therapy on recurrence-free survival (RFS). The multicenter I-SPY 1 TRIAL evaluated patients with ≥3 cm tumors by using early imaging and m...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Esserman, Laura J., Berry, Donald A., Cheang, Maggie C. U., Yau, Christina, Perou, Charles M., Carey, Lisa, DeMichele, Angela, Gray, Joe W., Conway-Dorsey, Kathleen, Lenburg, Marc E., Buxton, Meredith B., Davis, Sarah E., van’t Veer, Laura J., Hudis, Clifford, Chin, Koei, Wolf, Denise, Krontiras, Helen, Montgomery, Leslie, Tripathy, Debu, Lehman, Constance, Liu, Minetta C., Olopade, Olufunmilayo I., Rugo, Hope S., Carpenter, John T., Livasy, Chad, Dressler, Lynn, Chhieng, David, Singh, Baljit, Mies, Carolyn, Rabban, Joseph, Chen, Yunni-Yi, Giri, Dilip, Au, Alfred, Hylton, Nola
Formato: Artigo
Idioma:Inglês
Publicado: Springer US 2011
Assuntos:
Clinical Trial
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3332388/
https://ncbi.nlm.nih.gov/pubmed/22198468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-011-1895-2
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares